Որոնման արդյունքները - Tsai, Max
- Ցուցադրվում են 1 - 16 արդյունքները 16
-
1
-
2
Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol Tsai, Max, Case, Michael, Ardayfio, Paul, Hochstetler, Helen, Wilbraham, Darren
Հրապարակվել է 2020Տեքստ -
3
A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor Tsai, Max, Chrones, Lambros, Xie, Jinhui, Gevorkyan, Hakop, Macek, Thomas A.
Հրապարակվել է 2016Տեքստ -
4
A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis Naik, Himanshu, Tsai, Max C., Fiedler-Kelly, Jill, Qiu, Ping, Vakilynejad, Majid
Հրապարակվել է 2013Տեքստ -
5
The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus Dudkowski, Caroline, Tsai, Max, Liu, Jie, Zhao, Zhen, Schmidt, Eric, Xie, Jeannie
Հրապարակվել է 2016Տեքստ -
6
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects Wilbraham, Darren, Biglan, Kevin M., Svensson, Kjell A., Tsai, Max, Kielbasa, William
Հրապարակվել է 2020Տեքստ -
7
-
8
Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults Webb, Nicholas J. A., Wells, Thomas, Tsai, Max, Zhao, Zhen, Juhasz, Attila, Dudkowski, Caroline
Հրապարակվել է 2016Տեքստ -
9
-
10
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease Wilbraham, Darren, Biglan, Kevin M., Svensson, Kjell A., Tsai, Max, Pugh, Melissa, Ardayfio, Paul, Kielbasa, William
Հրապարակվել է 2021Տեքստ -
11
-
12
Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study Wilbraham, Darren, Berg, Paul H., Tsai, Max, Liffick, Emily, Loo, Li Shen, Doty, Erin Gautier, Sellers, Edward
Հրապարակվել է 2019Տեքստ -
13
A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationsh... Goldsmith, Paul, Affinito, John, McCue, Maggie, Tsai, Max, Roepcke, Stefan, Xie, Jinhui, Gertsik, Lev, Macek, Thomas A.
Հրապարակվել է 2017Տեքստ -
14
Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls Pearlman, Eric M., Wilbraham, Darren, Dennehy, Ellen B., Berg, Paul H., Tsai, Max, Doty, Erin G., Kay, Gary G.
Հրապարակվել է 2020Տեքստ -
15
Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine Tsai, Max, Nery, Emel Serap Monkul, Kerr, Lisa, Khanna, Rashna, Komori, Mika, Dennehy, Ellen B., Wilbraham, Darren, Winner, Paul
Հրապարակվել է 2021Տեքստ -
16
An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients Gilleen, James, Farah, Yakub, Davison, Cate, Kerins, Sarah, Valdearenas, Lorena, Uz, Tolga, Lahu, Gez, Tsai, Max, Ogrinc, Frank, Reichenberg, Avi, Williams, Steve C., Mehta, Mitul A., Shergill, Sukhi S.
Հրապարակվել է 2018Տեքստ